<div><div></div><div><span><ul><li><span>According to estimates from 20 analysts, Moderna, Inc. stock's average price target has risen from $47.05 to $47.45, with forecasts ranging from $22 to $135 per share</span></li><li><span>Based on the Jun. 24 closing price, the updated target implies approximately 21% potential downside</span></li><li><span>Consensus rating remains at “Hold” across 27 covering analysts, with 4 Buys, 18 Holds and 5 Sells</span></li></ul><p><span>Explore more price target data and ratings for Moderna, Inc. on the </span><span>, and track all previous and future analyst recommendations for Moderna, Inc. in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

MRNA

MRNX

MRNY

<p>Moderna's 12-month average price target was raised to $47.45 by 27 analysts, up from $47.05. Based on the June 24 closing price, this implies a 21% downside potential. The consensus rating remains 'Hold', comprising 4 Buys, 18 Holds, and 5 Sells.</p>

TradingView

Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside